Biotech · Public company · Watertown, MA, US
Disc Medicine, Inc.
Ticker IRON · SEC CIK 0001816736
Track this companyFree. Adds Disc Medicine, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials115 recruiting or active
Pipeline programs9From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availableNo recent cash burn filed
Pipeline9
- DISC-1459Phase 3 · Erythropoietic Protoporphyria (EPP)ClinicalTrials.gov · fetched Nov 12, 2026
- DISC-1459Phase 3 · Erythropoietic ProtoporphyriaClinicalTrials.gov · fetched Nov 12, 2026
- DISC-0974Phase 2 · Inflammatory Bowel Disease (IBD)ClinicalTrials.gov · fetched Nov 12, 2026
- DISC-0974Phase 2 · Myelofibrosis; AnemiaClinicalTrials.gov · fetched Nov 12, 2026
- DISC-3405Phase 2 · Polycythemia Vera (PV)ClinicalTrials.gov · fetched Nov 12, 2026
- DISC-0974Phase 1 · Chronic Kidney DiseasesClinicalTrials.gov · fetched Nov 12, 2026
- DISC-0974Phase 1 · Healthy VolunteerClinicalTrials.gov · fetched Nov 12, 2026
- DISC-3405Phase 1 · Healthy VolunteerClinicalTrials.gov · fetched Nov 12, 2026
- DISC-3405Phase 1 · Sickle Cell DiseaseClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials11
- Study of DISC-0974-201 in Participants With IBD and AnemiaPHASE2 · RECRUITING · started Feb 20, 2026ClinicalTrials.gov NCT07368972 · fetched Nov 12, 2026
- A Phase 1b, Open-Label Study of DISC-3405 in Participants With Sickle Cell Disease (SCD)PHASE1 · RECRUITING · started Jan 6, 2026ClinicalTrials.gov NCT07187973 · fetched Nov 12, 2026
- A Phase 2, Open-Label Study of DISC-3405 in Participants With Polycythemia Vera (PV)PHASE2 · ACTIVE_NOT_RECRUITING · started Aug 12, 2025ClinicalTrials.gov NCT06985147 · fetched Nov 12, 2026
- Study of Bitopertin in Participants With EPP or XLP (APOLLO)PHASE3 · COMPLETED · started Apr 4, 2025ClinicalTrials.gov NCT06910358 · fetched Nov 12, 2026
- A Study of DISC-3405 in Healthy VolunteersPHASE1 · COMPLETED · started Oct 3, 2023ClinicalTrials.gov NCT06050915 · fetched Nov 12, 2026
- HELIOS: Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Efficacy of DISC-1459 (Bitopertin) in Participants With EPP or XLPPHASE2_PHASE3 · ENROLLING_BY_INVITATION · started Aug 31, 2023ClinicalTrials.gov NCT05883748 · fetched Nov 12, 2026
- Study of DISC-0974 to Assess the Safety, Tolerability, PK and PD of DISC-0974 in Participants With CKD and AnemiaPHASE1 · COMPLETED · started Apr 4, 2023ClinicalTrials.gov NCT05745883 · fetched Nov 12, 2026
- Study of Bitopertin to Evaluate the Safety, Tolerability, Efficacy, and PPIX Concentrations in Participants With EPPPHASE2 · COMPLETED · started Oct 31, 2022ClinicalTrials.gov NCT05308472 · fetched Nov 12, 2026
- Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and AnemiaPHASE1_PHASE2 · RECRUITING · started Jun 6, 2022ClinicalTrials.gov NCT05320198 · fetched Nov 12, 2026
- Study to Evaluate the Safety, Tolerability, PK and PD of DISC-0974 in Healthy SubjectsPHASE1 · COMPLETED · started Aug 10, 2021ClinicalTrials.gov NCT04999527 · fetched Nov 12, 2026
- Expanded Access Program of Bitopertin For Participants With EPP or XLPAVAILABLEClinicalTrials.gov NCT07603401 · fetched Nov 12, 2026
SEC filings12
- 10-Q · 10-QSEC EDGAR · filed Nov 5, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Nov 5, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Oct 22, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Oct 19, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Sep 10, 2026 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed Jul 30, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Jul 30, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Jun 30, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Jun 24, 2026 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed May 5, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed May 5, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Feb 27, 2026 · fetched Nov 12, 2026